In a retrospective study on 140 patients analyzing a total of 497 cycles of [177Lu]Lu-PSMA-617, significant (grade ≥ 3) hematologic adverse events occurred in 13 (9.3%) patients, with anemia in 10 (7.1%), leukopenia in 5 (3.6%), and thrombocytopenia in 6 (4.3%) [28]. Here, FOLH1 is linked to anemia.